Day 1: Basics
- Key note lectures
- Who is at risk of developing atherosclerosis? – from Framingham to ‘Omics’
- Mechanisms of Atherogenesis
- Targets for molecular imaging
- Interventions to prevent coronary disease development
- Non-traditional risk factors
- Who will become vulnerable and when will it happen?
- How do we identify vulnerable myocardium, imaging or functionality test?
- “Grey” cases discussion: with or without clinical consequences

Day 2: Mechanisms and Imaging
- Intracoronary Imaging
- TECHNICAL CORNER
- Non-invasive imaging
- Biomechanical modelling
- Vulnerability: What to do after the event

Day 3: Treatment
- Mechanisms of plaque instability
- Thrombosis and antithrombotic therapies
- Treatment options for vulnerable plaques/patients
- TRIAL CORNER on PCSK-9
- Anti-inflammatory drug strategies
- Treatments to reduce patient vulnerability
- FINAL DEBATE Vulnerable Plaque - Simply a Myth or is the Requiem premature?
08:00 Welcome remarks
Prof. Patrick W. Serruys and guest director Prof. Bernard Gersh

KEY NOTE LECTURES
Moderators: Vilmundur Gudnason and Karl Andersen

08:05 What have I learned from VPM 2015? A 10,000 feet view
Patrick W. Serruys (NL)

08:25 The vulnerable population. The epidemic of CVD in the developing world: Global implications.
Bernard Gersh (USA)

08:45 Burning questions (5min)

Who is at risk of developing Atherosclerosis?
- from Framingham to ‘Omics’
Chairmen: Eric Peterson and Bernard Gersh

08:50 Precision medicine initiative– Dream or reality?
Eric Peterson (USA)

09:00 One burning question (3min)

09:03 From genome wide association to whole genome sequencing and epigenetics in CAD – What has been delivered and what can we expect?
Kari Stefansson (IS)

09:13 One burning question (3min)

09:16 Cardiovascular phenotyping in population studies – reclassification of CV risk in moderate/low risk individuals.
Vilmundur Gudnason (IS)

09:31 One burning question (3min)

09:34 Discussion (10 min.)
Mechanisms of Atherogenesis
Chairmen: Ramzi Khamis and Kari Stefansson

09:45  Ageing and the Biology of Atherosclerosis
       Toren Finkel (USA)
09:55  One burning question (3min)

09:58  Effect of DNA damage and repair on Atherosclerosis – a clinical perspective
       Martin Bennett (UK)
10:08  One burning question (3min)

10:11  Assessing oxidative stress, its impact on atherogenesis and predicting clinical outcomes
       Ramzi Khamis (UK)
10:21  One burning question (3min)

10:24  Discussion (10 min)

10:35  Coffee break (30 min)

Targets for molecular imaging
Chairmen: Marc Dweck and Rob Krams

11:05  Macrophages
       Farouc Jaffer (USA)
11:15  One burning question (3min)

11:18  Potential clinical imaging targets: hypoxia and haemorrhage
       Joe Boyle (UK)
11:28  One burning question (3min)

11:31  Anti-oxidised LDL antibodies from predicting risk in blood to imaging atherosclerosis.
       Ramzi Khamis (UK)
11:41  One burning question (3min)

11:44  Discussion (10 min)
Interventions to Prevent Coronary Disease Development
Chairmen: Farouc Jaffer and Martin Bennett

11:54 Focus on families and peer pressure– it works!  
Juan Alvira (ES)  
One burning question (3min)

12:04 Hypertension – Impact of Under-treatment on Global CVD burden implications of SPRINT.  
Eric Peterson (USA)  
One burning question (3min)

12:20 Cardiotoxicity of Tyrosine Kinase Inhibitors: Novel mechanisms and implications for atherosclerosis  
Ori Ben-Yehuda (USA)  
One burning question (3min)

12:33 Discussion (10 min)

12:45 Lunch Break

Non-traditional risk factors
Chairmen: Vilmundur Gudnason and Eric Peterson

14:15 Endothelial dysfunction and vasomotion  
Amir Lerman (USA)  
One burning question (3min)

14:25 Noninvasive assessment of Endothelial Function: Can it identify the Vulnerable Patient?  
Ori Ben-Yehuda (USA)  
One burning question (3min)

14:40 Sleep disorders and cardiovascular risk  
Bernard Gersh (USA)  
One burning question (3min)
Patients with chronic kidney disease
Lilach Lerman (USA)
One burning question (3min)

Discussion (15 min)

Who will become vulnerable and when will it happen?
Chairmen: Wolfgang Koenig and James Muller

Circulating biomarkers for predicting future cardiovascular risk – do we need more than high sensitivity troponin and BNP?
Stefan Blankenberg (DE)
One burning question (3min)

Beyond circulating biomarkers: In situ biomarkers assessment is essential to identify the vulnerable patients.
Nick West (UK)
One burning question (3min)

MSCT vs. PET-CT for identification of vulnerable patient – what PREFFIR will tell us.
Marc Dweck (UK)
One burning question (3min)

Discussion (10 min)

Coffee break (30 min)
How do we identify vulnerable myocardium, imaging or functionality test?
Chairmen: Amir Lerman and James Muller

16:40 I will use MSCT_{FFR} for risk stratification.
   Pamela Douglas (USA)
   One burning question (3min)

16:50

16:53 Don’t forget the importance of microcirculation
   Javier Escaned (ES)
   One burning question (3min)

17:03

17:06 Coronary vasospasm can cause plaque thrombosis
   Takashi Akasaka (JP)
   One burning question (3min)

17:16

17:19 Discussion (10 min)

“Grey” Cases Discussion: with or without clinical consequence

17:29 How do you treat your boss? Physiology- guided or IVUS-guided?
   Ramzi Khamis (UK)
   One burning question (3min)

17:39

17:42 How do you treat your boss? iFR-, FFR- or OCT-guided?
   Ranil de Silva (UK)
   One burning question (3min)

17:52

17:55 Discussion (5 min)
**Intracoronary Imaging**

*Chairmen: Ton van der Steen and Gregg Stone*

- **08:00** New development in intravascular ultrasound
  *Gary Mintz (USA)*
  *One burning question (3min)*

- **08:10** One burning question (3min)

- **08:13** New development in intravascular optical coherence tomography. (ESCORT Trial update)
  *Takashi Akasaka (JP)*
  *One burning question (3min)*

- **08:23** Multimodality catheter development: OCT-NIRS, OCT-NIRF and IVUS-NIRF
  *Farouc Jaffer (USA)*
  *One burning question (3 min)*

- **08:36** NIRS-IVUS for detection of vulnerable plaque.
  *David Erlinge (SE)*
  *One burning question (3min)*

- **08:39** Serial (5yrs) analysis of fused OCT IVUS GS and IVUS VH. What does multimodality imaging add?
  *Patrick W. Serruys (NL)*
  *One burning question (3min)*

- **09:02** Discussion (15 min)

**09:20** TECHNICAL CORNER (5 slides - 5 min.)

- NIRS as a possible tool to detect erosion sites
  *James Muller (USA)*

- Combined catheter of OCT-IVUS
  *Yoshi Onuma (NL)*

- Heartbeat OCT
  *Ton van der Steen (NL)*

- Photo-acoustic imaging
  *Ton van der Steen (NL)*

- **09:40** Discussion (10 min)
Brillouin imaging
Rob Krams (UK)

Time-Resolved Spectroscopy IVUS
Christos Bourantas (UK)

X-ray angiography-derived FFR and shear stress
Jean-Paul Aben (NL)

High Definition IVUS - The ACIST HDi System
Gary Mintz (USA)

Discussion (10 min)

Innovations in software and post-processing
Yoshi Onuma (NL)

One burning question (3min)

Coffee break (30 min)

Non-invasive imaging
Chairmen: Udo Hoffmann and Gary Mintz

The relationship between invasive and non-invasive imaging for vulnerable plaques.
James Muller (USA)

One burning question (3min)

Culprit and vulnerable plaque in CT (Trial Updates)
Udo Hoffmann (USA)

One burning question (3min)

Dixon MRI
Jouke Smink (NL)

One burning question (3min)

MRI for plaque vulnerability
Rene Botnar (UK)

One burning question (3min)
11:52 Update of PESA: MRI
Juan Alvira (ES)
One burning question (3min)

12:02 Panel discussion (20 min)
• Will we ever solve the problem of vulnerable plaque with intravascular imaging?
• We will solve the problem with non-invasive imaging.
• No imaging needed.

12:25 Lunch Break

Biomechanical modelling
Chairmen: Peter Stone and Ton van der Steen

13:45 Haemodynamic determinants of advanced coronary plaque formation
Ranil de Silva (UK)
One burning question (3min)

13:55 Shear stress is the determinant of neoatherosclerosis and stent failure
Christos Bourantas (UK)
One burning question (3min)

14:08 What influences plaque progression and vulnerability most: High shear stress, low shear stress, or oscillatory shear stress?
Jolanda Wentzel (NL)
One burning question (3min)

14:24 Linking haemodynamics with biology – systems biology of advanced atherosclerotic plaque formation
Rob Krams (UK)
One burning question (3min)

14:37 Applying shear stress to PROSPECT
Peter Stone (USA)
One burning question (3min)
Is shear stress ready for prime time? Feasibility of on-line analysis and what decision could be made based on shear stress.

Academic Perspective: Frank Gijsen (NL)
What we need from industry: Christos Bourantas (UK)

One burning question (3min)

Discussion (20 min)

Vulnerability: What to do after the event
Chairmen: Ramzi Khamis and James Muller

Cardioprotection after reperfusion – it works in animals but why not in patients?

Bernard Gersh (USA)

One burning question (3min)

Intracoronary infusion of Adenosine perfusion in preclinical model

Dirk-Jan Duncker (NL)

One burning question (3min)

Cooling for myocardial infarction: How much, how soon?

Marko Noč (SL)

One burning question (3min)

Discussion (10 min)
Mechanisms of plaque instability
Chairmen: Rob Krams and Martin Bennett

08:00  Observations from sudden cardiac death patients – how do they relate to our patients presenting with ACS?
  Michael Joner (DE)

08:10  One burning question (3min)

08:13  The temporal shift in plaque characteristics underlying clinically manifest of atherosclerotic disease.
  Gerard Pasterkamp (NL)

08:23  One burning question (3min)

08:26  Porcine models of vulnerable plaque: Apo E knockout minipigs
  Jacob Fog Bentzon (ES)

08:36  One burning question (3min)

08:39  Humoral immunity and plaque vulnerability
  Ramzi Khamis (UK)

08:49  One burning question (3min)

08:52  Intra-plaque haemorrhage and hypoxia – potential diagnostic and therapeutic targets
  Joe Boyle (UK)

09:02  One burning question (3min)

09:05  Discussion (15 min)
09:20  Bivalirudin and Cangrelor - From one Horizon to the next.  
**Gregg Stone (USA)**  
One burning question (3min)

09:30  Prolongued antiplatelet therapy: who really needs it, and is it treating stents or vulnerable plaque?  
**Patrick W. Serruys (NL)**  
One burning question (3min)

09:43  Discussion (5 min)

09:55  Coffee break (30 min)

10:25  PCSK9 metabolism: from synthesis to expression  
**Jochen Maas (DE)**  
One burning question (3min)

10:35  ALN-PCSSc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis  
**David Kallend (CH)**  
One burning question (3min)

10:48  Hs-CRP and PCSK-9 after ACS: Lessons learned from IBIS-4  
**Lorenz Räber (CH)**  
One burning question (3min)

11:04  Apo-AI Milano  
**Peter Wijngaard (CH)**  
One burning question (3min)

11:17  Discussion (15 min)
11:32  TRIAL CORNER on PCSK-9 (5 slides - 5 min)
FOURIER trial  Ricardo Dent
ODYSSEY outcomes trial  Timothée Sourdille
SPIRE I/II trials  James Revkin

11:50   Panel discussion of trialists
Gregg Stone, Bernard Gersh, Wolfgang Koenig,
Amir Lerman, Patrick W. Serruys ,........

12:05   Lunch Break

Anti-inflammatory drug strategies
Chairmen: Ramzi Khamis and Bernard Gersh

13:35   Targeting CD40-CD40L
Esther Lutgens (NL)

13:45   One burning question (3min)

13:48   Lessons learned from biomarker analysis of STABILITY.
Wolfgang Koenig (DE)

13:58   One burning question (3min)

14:01   CIRT, CANTOS and COLCOT Trials – Rationale and Progress
Wolfgang Koenig (DE)

14:11   One burning question (3min)

14:14   Discussion (10 min)

Treatments to reduce patient vulnerability
Chairmen: James Muller and John Ambrose

14:24   Why do we need the ISCHEMIA trial?
Gregg Stone (USA)

14:34   One burning question (3min)

14:38   How vulnerable are patients with refractory angina?
Ranil de Silva (UK)

14:48   One burning question (3min)
14:51  Biomarkers and IVUS for risk prediction – what did we learn from ATHEROREMO and BIOMArCS study?  
Eric Boersma (NL)  
One burning question (3 min)

15:01  One burning question (3 min)

15:04  IBIS-4: Effects of high-intensity statin therapy on OCT and VH-IVUS derived vulnerability parameters  
Lorenz Räber (CH)  
One burning question (3 min)

15:17  Treatment of Vulnerable Plaque  
From PROSPECT: ABSORB to PREVENT (with case examples)  
Gregg Stone (USA)  
One burning question (3 min)

15:30  Discussion (15 min)

15:45  FINAL DEBATE: Vulnerable Plaque- Simply a Myth or is the Requiem premature?  
Vulnerable plaque does not exist. Stop wasting your time and our money. A clinician’s view.  
John Ambrose (USA)

15:55  Thirteen years of VPM and the search for the vulnerable plaque – Now we are getting somewhere!!  
James Muller (USA)

16:05  Discussion (10 min)

16:15  Closing remarks:  
Board of directors (Patrick W. Serruys, Gregg Stone, Ton van der Steen, Wolfgang Koenig, Amir Lerman, James Muller and Gerrit-Anne van Es)  
Guest director: Bernard Gersh
GENERAL INFORMATION

The Meeting will be held from June 26th - June 28th, 2016, at the Hilton Reykjavik Nordica Hotel.

CONGRESS LOCATION & VENUE

HILTON REYKJAVIK NORDICA HOTEL
Sudurlandsbraut 2, Reykjavik, 108, Iceland
Tel.: +354-444-5000 Fax: +354-444-5001

Set in the city center, the stylish Hilton Reykjavik Nordica hotel is one of the city’s most popular destinations for tourists, business travelers and locals alike. Its central location provides a great base from which to discover the capital, and makes it easy to travel further afield and explore Iceland’s unspoiled natural landscapes.

SCIENTIFIC PRESENTATIONS

The Meeting rooms will be equipped with Screen, Data Video Projector for Microsoft Power Point presentations, Note pads, pens and laser pointers. Please download your presentation at the meeting secretariat before your session starts.

TRANSFER SERVICES FROM/ TO AIRPORT

Transfer services will be available to/from the Hilton Nordica Reykjavik Hotel, according to your flight itinerary. Kindly note, that there will be a transfer service arranged for you upon your arrival and departure. Please note that the pick-up time regarding your departure will be 3hrs & 30mins prior your flight.

SPECIAL THANKS TO

MEETING SECRETARIAT & OFFICIAL TRAVEL AGENCY

The Meeting’s Secretariat will operate during meeting hours.